The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patient characteristics, treatment, and outcomes in recurrent HR+/HER2- advanced breast cancer after adjuvant therapy: A retrospective chart review of community-based practice.
Yanni Hao
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Peggy L. Lin
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Alexander R. Macalalad
Consultant or Advisory Role - Novartis
Research Funding - Novartis
James E. Signorovitch
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Eric Qiong Wu
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Zhou Zhou
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Jinlin Song
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Erika Ohashi
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Caroline Kelley
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Suleiman Alfred Massarweh
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Bayer; Novartis